Profound Medical Corp. (PROF)
| Market Cap | 274.92M |
| Revenue (ttm) | 14.30M |
| Net Income (ttm) | -39.34M |
| Shares Out | 30.19M |
| EPS (ttm) | -1.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 107,564 |
| Open | 7.72 |
| Previous Close | 7.78 |
| Day's Range | 7.55 - 7.99 |
| 52-Week Range | 3.76 - 8.95 |
| Beta | 0.36 |
| Analysts | Strong Buy |
| Price Target | 12.00 (+57.69%) |
| Earnings Date | Mar 5, 2026 |
About PROF
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company’s lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prosta... [Read more]
Financial Performance
In 2024, Profound Medical's revenue was $10.68 million, an increase of 48.35% compared to the previous year's $7.20 million. Losses were -$27.82 million, -1.79% less than in 2023.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for PROF stock is "Strong Buy" and the 12-month stock price target is $12.0.
News
Profound Medical (PROF) Celebrates Milestone in Poland with 500th Sonalleve Procedure
Profound Medical (PROF) Celebrates Milestone in Poland with 500th Sonalleve Procedure
Profound Medical (PROF) Introduces TULSA-PRO at Mount Sinai Hospital
Profound Medical (PROF) Introduces TULSA-PRO at Mount Sinai Hospital
Profound Medical (PROF) Surpasses Installation Goal with TULSA-PRO System
Profound Medical (PROF) Surpasses Installation Goal with TULSA-PRO System
Profound Medical (PROF) Sees Price Target Boost by Lake Street | PROF Stock News
Profound Medical (PROF) Sees Price Target Boost by Lake Street | PROF Stock News
Profound Medical (PROF) Marks Milestone at Johns Hopkins Hospital
Profound Medical (PROF) Marks Milestone at Johns Hopkins Hospital
Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case
Profound Medical marks major milestone as the hospital launches its state-of-the-art iMRI suite to expand access to advanced prostate care Profound Medical marks major milestone as the hospital launch...
Profound Medical Corp. Announces Closing of Private Placement
TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private pla...
Profound Medical increases private placement to $6.45M
Profound Medical Corp. Announces Upsize of Private Placement
TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has increased the size of its private placement pr...
Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th
Financing included participation by healthcare-dedicated investors alongside existing shareholders Financing included participation by healthcare-dedicated investors alongside existing shareholders
Profound Medical announces pricing of up to $40 million financing
Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement
TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (Nasdaq:PROF; TSX:PRN) (“Profound” or the “Company”) today announced the sale of 5,142,857 common shares at a purchase price of $7.00 ...
Wall Street Analysts Think Profound Medical (PROF) Could Surge 82.37%: Read This Before Placing a Bet
The consensus price target hints at an 82.4% upside potential for Profound Medical (PROF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...
Stanford Medicine's Dr. Pejman Ghanouni Receives RSNA's Cum Laude Award for CAPTAIN Perioperative Data Presentation
– CAPTAIN is the first randomized controlled trial ever comparing a new technology to the standard of care of robotic radical prostatectomy to successfully recruit to target – – CAPTAIN is the first r...
Profound Medical (PROF) Readies Launch of TULSA-AI Module for BPH Treatment
Profound Medical (PROF) Readies Launch of TULSA-AI Module for BPH Treatment
Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings
New BPH module and clinical data reinforce the TULSA Procedure™'s versatility in prostate disease, superior patient benefits, and potential for mainstream adoption New BPH module and clinical data rei...
Profound Medical (PROF) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Profound Medical (PROF), indicating that the stock has found support. This, combined with an upward trend in earnings estimat...
Profound Medical (PROF) Just Flashed Golden Cross Signal: Do You Buy?
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Profound Medical (PROF) Upgraded to Buy: What Does It Mean for the Stock?
Profound Medical (PROF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Believe Profound Medical (PROF) Could Rally 97.59%: Here's is How to Trade
The consensus price target hints at a 97.6% upside potential for Profound Medical (PROF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...
Profound Medical Celebrates The Hong Center's 200th Independent TULSA Procedure for Prostate Disease
Renowned urologist Dr. Mark Hong sets new global benchmark for urologist-led, MRI-guided prostate treatment, leading a growing movement toward incision-free prostate therapy Renowned urologist Dr. Mar...
Profound Medical (PROF) Surpasses Q3 Revenue Expectations
Profound Medical (PROF) Surpasses Q3 Revenue Expectations
Profound Medical (PROF) Achieves Record Q3 Revenue and Growth
Profound Medical (PROF) Achieves Record Q3 Revenue and Growth
Profound Medical Corp. (PRN:CA) Q3 2025 Earnings Call Transcript
Profound Medical Corp. ( PRN:CA) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Stephen Kilmer - Investor Relations Rashed Dewan Mathieu Burtnyk - President Thomas Tamberrin...
Profound Medical (PROF) Reports Strong Q3 Performance Despite Revenue Miss
Profound Medical (PROF) Reports Strong Q3 Performance Despite Revenue Miss